2nd Annual Biosimilars Summit

This innovative B2B event will enable the participants to learn about the latest trends of the Biosimilars, commercialization aspects, regulatory advises and strategies for Biosimilars development. As biosimilars are now being developed and manufactured using todays state of the art technology and techniques, they can potentially also offer some benefits, in addition to cost, over the reference biologics. It is proved that Biosimilars could save the U.S. health system close to $44 billion in the next ten years.

#BiosimilarsBerlin
FACEBOOK EVENT

Key Practical Learning Points of the Summit:

  • The latest trends of the biosimilars
  • Successful commercialization of biosimilars in Europe and USA
  • Biosimilars in emerging markets – Regulatory and commercial considerations
  • Industry partnerships: Key success factor to win in biosimilar space
  • Regulatory advice on designing biosimilar trials
  • Totality of evidence and what it means to clinician
  • Experience of global clinical biosimilar trials
  • Strategies and competing products for a successful commercialization

Who Should Attend:

Chief Executives, Executive Directors, VPs, Department Heads, Team Leaders and Managers from:

  • Biologics/Biotechnology/ Biogenerics
  • Biopharmaceuticals
  • Legal Affairs
  • Intellectual property
  • Pricing and Reimbursement
  • Clinical Immunology
  • Regulatory Compliance
  • R&D
  • Preclinical and Clinical Development
  • New Product Development
  • Quality Affairs/ Quality Control
  • Pharmacovigilance

From Industries Including: 

  • Clinical Immunology
  • Oncology
  • Immunology
  • Infection and Immunity
  • Drug Safety
  • Risk Management
  • Preclinical Development
  • Clinical Program
  • Therapeutic Areas
  • Personalized Medicine
  • Business Development
  • Portfolio Planning
  • Vaccines Development
  • Regulatory Affairs
  • Scientific Affairs
  • Validation
  • Global Strategy
  • Analytical Characterization
  • Antibody Engineering
  • Antibody Discovery

 

Speakers
Sponsors
Media partners

Previous Year Attendees

  • AGES / Austrian Medicines & Medical Devices Agency, Austria
    Senior Clinical Expert

  • Boehringer Ingelheim, Germany
    Head of Global Regulatory CMC Strategy Biosimilar

  • BOEHMERT & BOEHMERT, Germany
    Senior Patent Attorney

  • Biotech, Switzerland
    Senior Advisor Pharma

  • Celonic AG, Germany
    Senior Director Business Development

  • Cinfa Biotech GmbH, Germany
    Director Business Development

  • Greenovation Biotech, Germany
    CEO

  • Hospira, Spain
    Technical and Regulatory Affairs Manager

  • Hospira, UK
    Vice President - Biologics

  • InSight Biopharmaceuticals, Israel
    Executive Vice President

  • ImmunXperts, Belgium
    Chief Technology Officer

  • Kiecana Sp. Z o.o., Poland
    Research and Development Director

  • Kiecana Sp. Z o.o., Poland
    CEO

  • KCR SA, Italy
    Director, Business Development

  • Merck Serono, Switzerland
    Director Portfolio Management & Strategy

  • Merck Serono S.p.A., Italy
    Site Molecule Expert

  • Merck Serono, Switzerland
    Head of Safety, Biosimilars

  • Multipharma, USA
    Business Development Manager

  • Novartis, Switzerland
    Head Clinical Pharmacology

  • Novartis, Switzerland
    Investor Relations

  • Norwegian Medicines Agency, Norway
    Medical Director

  • PRA International, UK
    Executive Director Biosimilar Development 

  • Pfizer Pharma GmbH, Germany
    Lead Customer Affairs & Access GIPB

  • Pfizer Pharma GmbH, Germany
    Lead Business Operations & Commercial Excellence

  • Pfizer Pharma GmbH, Germany
    Manager Access Inflammation

  • Pfizer Corporation, Austria
    Director, Commercial Development Lead of Biosimilars

  • Roche Pharma AG, Germany
    Payer Strategy Manager

  • Sanofi, Turkey
    Head of Regulatory Affairs & Product Patrimony

  • SGS Life Science Services, UK
    Global Director, BioPharma Services Development